Radius Health

Radius Health is NOW Part of Paratek Pharmaceuticals Learn more about our company and growing commercial portfolio of differentiated specialty medicines for patients with significant medical needs: paratekpharma.com/investor-r…

Hear Dr. Richard Eastell describe recent results on #bone turnover markers as a way to predict changes in bone mineral density in #men with #osteoporosis published in #JBMR smithbucklinvoices.gv-one.co…

Radius is proud to celebrate World Quality Day! It’s a time to reflect on the processes, practices, and commitment required to ensure excellence in all that we do. #WorldQualityDay vimeo.com/1029666786/e439de4…

We are presenting #newdata at #ENDO2024 @TheEndoSociety on #BoneTurnoverMarkers #oralcommunication on June 2nd at 1:45 PM, 257ABC and #MalePredictiveModel #poster on June 3rd at 12PM abstract 7459 #Osteoporosis #BoneHealth

White is the color of #OsteoporosisAwareness, and our team represented by wearing white on the same day to show our support for bone health. Here are just some of our team members who participated - both in person and virtually!

At Radius, we embrace the importance of #collaboration and #givingback, and last week's offsite was no exception. We came together, to build #bikes as a team. The bikes were then donated to the Phoenixville Community Education Foundation that supports low income families.

We are presenting new #RWE data on #hipfracture at #WCO2024 #IOF-ESCO #oralcommunication on April 12 at 10am GMT in the Auditorium A Presented by: Professor JY Reginster

Radius is excited to be at #WCO2024 #IOF-ESCO raising awareness on #osteoporosis and #hipfracture in #postmenoposalwomen

Our partner in Japan, Teijin Pharma, announced that they have launched #abaloparatide for #osteoporosis in Japan. Read the full release here: bit.ly/3l2R7ZC

Stemline Therapeutics Inc. receives approval from U.S. #FDA for ORSERDU (#elacestrant) as the first and only treatment specifically indicated for patients with ESR1 Mutations in ER+, HER2- advanced or metastatic breast cancer. Read the full release here: bit.ly/3XPA7EF

Today we are proud to announce the U.S. FDA has approved our treatment to help men with osteoporosis. For more information, visit bit.ly/3WsyzPS #FDA #Osteoporosis

On #worldosteoporosisday – and every day – Radius is committed to bone health. If you suffer a broken bone over the age of 50, take #actionforbonehealth and ask your doctor for post-fracture care to help prevent secondary fractures.

Worldwide, 1 in 3 women over age 50 will experience an osteoporotic fracture. Radius continues its commitment to bone health and on #worldosteoporosisday we urge everyone to take #actionforbonehealth.

Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc. bit.ly/3pqLVO5

Today we announced the first #patient has been randomized in the #RAD011 Phase 2/3 pivotal study for Prader-Willi Syndrome. bit.ly/3Ay0iHa #praderwillisyndrome #PWS #SCOUT015 @PWSAUSA @ipwso @fpwr

Today Radius Health announced an agreement to be acquired by Gurnet Point Capital and Patient Square Capital. Radius will host a call at 9:30 a.m. ET today to review the proposed transaction. Read the press release here bit.ly/3ydPPz4

Along with Menarini Group, today we announced a New Drug Application submission to the #FDA for #elacestrant in patients with ER+/HER2- advanced or metastatic breast cancer. Read the full release here: bit.ly/3QJlyzp #nda #oncology

Radius continues its focus on the global business expansion of TYMLOS (abaloparatide) subcutaneous injection. Today we announced that we have entered agreements that add 13 new countries to the current non-US markets of Japan and Canada. bit.ly/3totmfV

Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 #EMERALD clinical trial at the @ASCO 2022 Annual Meeting bit.ly/3MmfPMG #ASCO22 #oncology

Today we provided an update on the abaloparatide transdermal system development program. Read the full release below. ir.radiuspharm.com/news-rele…